Related Experiment Videos
Biologic and New Therapies in Asthma
Farnaz Tabatabaian1, Dennis K Ledford2, Thomas B Casale3
1Division of Allergy and Immunology, Department of Internal medicine, Morsani College of Medicine, University of South Florida, 13330 USF Laurel Dr. 5th Floor, MDC 80, Tampa, FL 33612-4799, USA.
Immunology and Allergy Clinics of North America
|April 4, 2017
Summary
Severe asthma patients lacking Th2-high biomarkers have limited treatment options. Current Th2-targeting therapies do not offer persistent immunomodulation or remission for these individuals.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Several FDA-approved biologics target Th2-high asthma.
- Severe asthma affects 50% of patients who do not fit the Th2-high phenotype.
- These patients have fewer effective therapeutic options.
Purpose of the Study:
- To highlight the unmet need for effective therapies in severe asthma patients lacking Th2-high biomarkers.
- To discuss the limitations of current Th2-targeting treatments.
- To emphasize the lack of precise biomarkers for predicting treatment response within Th2-high asthma.
Main Methods:
- Review of current clinical tools for defining Th2-high asthma (total IgE, FeNO, peripheral blood eosinophils).
- Analysis of the efficacy and limitations of existing Th2-targeting biologics.
- Discussion of the need for novel biomarkers and therapeutic strategies.
Main Results:
- Current biomarkers (total IgE, FeNO, eosinophils) define Th2-high asthma but do not predict response to specific Th2-therapies.
- A significant portion of severe asthma patients (50%) do not respond to Th2-targeted treatments.
- Existing Th2 pathway medications do not induce persistent immunomodulation or remission.
Conclusions:
- There is a critical need for improved therapeutic strategies for severe asthma patients who are not Th2-high.
- Development of precise biomarkers is essential to guide treatment selection for Th2-high asthma.
- Current Th2-targeting therapies offer limited long-term benefits, lacking persistent immunomodulation or remission.